NCT03715478 - Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

June 1, 2025

Study Completion Date

December 31, 2026

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG

GSK2857916 with Pomalidomide and Dexamethasone

Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.

Trial Locations (9)

Unknown

Cross Cancer Institute, Edmonton

Vancouver General Hospital, Vancouver

CancerCare Manitoba, Winnipeg

QEII Health Sciences Centre, Halifax

Juravinski Cancer Centre, Hamilton

London Health Sciences Centre, London

The Ottawa Hospital, Ottawa

Princess Margaret Cancer Centre, Toronto

Allan Blair Cancer Centre, Regina